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ABSTRACT 
Aims 
Diagnosis of inflammatory bowel disease (IBD) is often associated with a diagnostic 
delay. Although fecal calprotectin is a helpful screening tool, the widespread use in 
primary care (PC) may not be appropriate due to the low prevalence of IBD in this 
setting. To increase pretest-probability for a positive calprotectin test, an 8-item-
questionnaire (CalproQuest) was tested for its feasibility and acceptability in PC.  
Methods 
Population: PC patients with unspecific gastrointestinal complaints for at least 2 weeks. 
The CalproQuest consists of 4 major and 4 minor questions specific for IBD. It is 
considered positive if ≥ 2 major or 1 major and 2 minor criteria are positive. Primary 
outcome: feasibility of CalproQuest, secondary outcome: patient’s acceptance of stool 
sampling. 
Results 
Of 95 patients with a complete CalproQuest 52 (54.7%) were positive, 39 (41.1%) 
fulfilled 2 major and 13 (13.7%) 1 major and ≥ 2 minor criteria. 27 general practitioners 
completed 83 (87.4%) questionnaires on feasibility which was assessed positive. 82 
patients (86.3%) completed questionnaires on acceptance which was high.  
Conclusion 
The CalproQuest is a feasible instrument for assessing IBD in PC. Further prospective 
studies concerning validity and cost-effectiveness of a combined use with the 
calprotectin test in this setting are necessary. 
 
Trial registration number: ISRCTN66310845 
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INTRODUCTION 
Abdominal pain is one of the most frequent symptoms in primary care1,2. In the US, 
where respective data have been collected, 2.5 million consultations due to abdominal 
pain were recorded per year3.  General practitioners (GP) often face the diagnostic 
challenge of identifying patients in need for further diagnostics and differentiating 
patients with inflammatory bowel disease (IBD) from functional disorders such as 
irritable bowel syndrome (IBS). Crohn’s Disease (CD), ulcerative colitis (UC) and 
indeterminate colitis (IC) represent the three subtypes of IBD4. Estimated prevalence of 
IBD in the Swiss population is 205 cases per 100’000 (0.2%) 5. Meanwhile, the 
prevalence of irritable bowel syndrome (IBS) in Europe and North America is estimated 
at 10 – 15% 6. Symptoms similar to IBS are frequently reported in patients before IBD 
is diagnosed7. Difficulties in recognizing early IBD, especially in primary care, lead to 
considerable diagnostic delay in IBD4, which has been shown to correlated with an 
increased risk of bowel stenosis and CD-related intestinal surgery8.  
The gold diagnostic standard for IBD is endoscopy. However, not every patient with 
abdominal discomfort or pain in primary care can be investigated by means of an 
invasive endoscopic exam. Therefore, different non-invasive markers were developed 
to reduce the number of necessary endoscopies and hence to increase the likelihood 
of positive endoscopic results. Several studies, mainly originated in specialist care, 
have shown that fecal calprotectin reflects intestinal inflammation in patients with 
known IBD9, 10-12, 13-15. It has also been shown to differentiate IBD from IBS due to its 
good negative predictive value in discriminating IBD versus IBS, depending on the 
cutoff value used16, 17, 18 , 19. Although calprotectin tests are easily accessible and 
reimbursed in Switzerland, this diagnostic test is not routinely performed in primary 
care. The reasons here fore have not yet been systematically elaborated; we assume 
the following considerations to play a role: a) the low prevalence of IBD in general 
practice. When analyzing the reasons for encounter in primary care, it becomes clear 
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that digestive disorders are frequent complaints with a prevalence of 5-7%20,21. 
Considering the population-based prevalence of 10-15% of IBS compared with 0.2% of 
IBD, IBS is much more common in primary care. b) This consideration combined with 
the large amount of differential diagnosis for a positive calprotectin test besides IBD 
(esophagitis, gastritis, gastric ulcers, celiac disease, polyps and carcinomas, infections 
gastroenteritis, diverticulitis, microscopic and ischemic colitis, NSAR enteropathy, use 
of proton pump inhibitors, lactose intolerance) narrow the utility of the calprotectin test 
in this setting, besides c) the relatively high costs (currently about 60 Euros).  
Data assessing the diagnostic accuracy of the calprotectin in the primary care setting is 
scarce. In this setting, the pretest probability for a positive calprotectin is naturally low 
due to low prevalence of IBD. It is hence not astonishing that studies from primary care 
indicate a questionable diagnostic accuracy22-25. To increase pretest-probability for a 
positive calprotectin test and hence to increase its utility in the primary care setting, an 
8-item-questionnaire (CalproQuest) was tested for its feasibility in primary care.  
 
METHODS AND ANALYSIS 
Ethics, trial registration, informed consent and funding 
 Ethics: The study protocol was approved by the Ethics Committee of the Kanton 
Zurich (reference KEK-ZH-number 2013-0516). 
 The study protocol conforms to the ethical guidelines of the 1975 Declaration of 
Helsinki as reflected in a prior approval by the institution's human research 
committee. 
 Trial registration number: ISRCTN66310845. 
 Written, informed consent was obtained from each patient included in the study. 
 Fundig: This project is supported by grants from the IBDnet, Swiss Research 
and Communication Network on Inflammatory Bowel Disease, and the 
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“Gottfried und Julia Bangerter-Rhyner-Stiftung”, fund of the Swiss Academy of 
Medical Sciences. The funding sources had no role in the design of this study 
and will not have any role during its execution, analyses, interpretation of the 
data, or decision to submit results. 
 
Study design 
This study is a part of the prospective diagnostic ALERT trial (VAlidation of an 8-item-
questionnaire predictive for a positive caLprotectin tEst and Real-life implemenTation in 
primary care to reduce diagnostic delay in inflammatory bowel disease), consisting of 
two independent parts A and B, conducted by gastroenterologists (A) and GPs (B). The 
details of the study design, including recruitment of patients and physicians, 
administration of patient records, informed consent and confidentiality have been 
published previously26.. Patients included in the study presented at their GP because of 
on-going unspecific gastrointestinal symptoms for at least two weeks (abdominal pain, 
bloating, stool irregularities, diarrhea). The study design and including the study flow is 
shown in Figure 1. 
 
Inclusion and exclusion criteria 
Inclusion criteria:  
  18 years  
 GP visit due to on-going unspecific gastrointestinal symptoms (abdominal pain, 
bloating, stool irregularities, diarrhea) for at least two weeks  
 No earlier diagnostic procedures (endoscopy) for the current episode 
 Informed consent 
 
Exclusion criteria:  
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 < 18 years 
 Known further/other abdominal pathologies as e.g. cancer 
 Previous abdominal surgeries 
 Treatment with steroids (topical and/or oral) and/or amino salicylates within 30 
days prior inclusion into this study 
 Endoscopic examination within 3 years prior screening 
 
Procedure (see also Figure 1) 
- Patients were subjected to CalproQuest.  
- Patients obtained fecal samples to measure calprotectin levels. Besides the possible 
diagnostic utility concerning the patient’s complaints, the calprotectin was measured 
also in order to test for patient acceptance of stool sampling. No statement is possible 
concerning the validation of the CalproQuest with the calprotectin measures due to 
under powering.  
- Patients completed the questionnaire on acceptance of stool sampling and physicians 
completed the questionnaire on feasibility of CalproQuest in daily practice. 
- According to the current standard of care, patients with calprotectin levels ≥ 50 μg/g 
were referred to a gastroenterologist for endoscopic examination. It was at the 
discretion of the GP to follow this advice. The GP was informed about results of the 
endoscopy and he forwarded these results to the study center.   
 
CalproQuest  
CalproQuest is an 8-item IBD-questionnaire consisting of 4 major and 4 minor 
questions specific for IBD (Table 1). The CalproQuest is considered positive, if  2 
major criteria or 1 major criterion and 2 minor criteria are answered positively. We 
assumed that a positive CalproQuest result might predict calprotectin levels  50 μg/g. 
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Calprotectin levels above 50 μg/g are indicative for on-going intestinal inflammation 
and call for further endoscopic examination. 
 
Fecal Calprotectin 
Fecal calprotectin levels were measured at the University Hospital Zurich. Specimens 
from outpatients were sent to the laboratory by post. The calprotectin test is called EliA 
calprotectin (Thermo Fisher Scientific) and uses the FEIA method (fluorescence 
enzyme immunoassay) on a fully automated system called Phadia 100. The EliA 
calprotectin Wells are coated with monoclonal antibodies to calprotectin. If present in 
the patient's specimen, calprotectin binds to the coated antibodies. After washing away 
non-bound components, enzyme-labeled antibodies against human calprotectin 
(EliACalprotectin Conjugate) are added to form a calprotectin-conjugate complex. After 
incubation, non-bound conjugate is washed away and the bound complex is incubated 
with a development solution. After stopping the reaction, the fluorescence in the 
reaction mixture is measured. The higher the response value, the more calprotectin is 
present in the specimen. To evaluate test results, the response for patient samples is 
compared directly to the response for calibrators. 
 
Questionnaires 
The contents of the physician’s questionnaire on feasibility and acceptance of 
CalproQuest in primary care and the patient questionnaire on acceptance of stool 
sampling are provided within the Figures 2 and 3.  
 
Primary and secondary outcomes 
Primary outcome: Feasibility of CalproQuest in daily primary care practice. 
Secondary outcome: Patient-reported acceptance of stool sampling.  
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Statistical analysis 
Likert-bar plots visualize feasibility of the CalproQuest and the patient-reported 
acceptance.  For the comparison of symptoms of patients with a positive or negative 
calprotectin a Chisquare-Test was performed. p<0.05 is considered statistically 
significant. Statistical analysis was performed with R (R version 3.3.2)27.  
 
 
 
RESULTS 
 
Population 
Recruitment of GP’s started in October 2014 and ended in November 2016. 
Recruitment was performed by means of information events as well as mailings and 
personal contacts of the involved team. Therefore, no actual non-responder list was 
compiled. The study flow and Consort statement is shown in Figure 1 and Appendix 1. 
From 40 GPs, which were initially instructed, 35 finally agreed to participate and 
recruited patients. During study, one GP dropped out. The 34 GPs were mainly male 
(25, 73.5%), with a mean age of 49.4 years and working in practice since mean 12.4 
years, mainly in group practices (30, 85.7%). 26 (76.5%) GPs had used a calprotectin 
test before participating in the study.  
The 34 GPs recruited between one and 7 patients (mean 3.1), in total 98. From the 98 
CalproQuests 95 were complete. 84 patients (mean (SD) age 38.0 (14.5) years, 57.1% 
female) with complete CalproQuests underwent calprotectin testing. From the 95 
CalproQuests 52 (54.7%) were positive, 39 (41.1%) fulfilled 2 major criteria and 13 
(13.7%) fulfilled one major and ≥ 2 minor criteria. In 15 (15.8%) fecal probe 
concentrations of ≥50µg/g calprotectin were found. In 9 (9.5%) the CalproQuest was 
likewise positive. The most common symptoms were abdominal pain (78, 80.4%) and 
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diarrhea (37, 38.1%). The most common minor criteria were fatigue (55, 56.7%) and 
slime in feces (28, 28.9%). The distribution of symptoms did not show any significant 
difference between patients with calprotectin concentrations above or below 50µg/g 
(p=0.8896).   
Since according to the study protocol it was not mandatory for the GP to send patients 
with a positive Calprotectin to endoscopic evaluation the data we received concerning 
endoscopic and histologic findings is far from complete. GPs sent the results of 5 
endoscopies to the study center, of which 4 showed either no pathological findings or 
diverticulosis and/or polyps/adenomas, one showed evidence of CD.   
 
Primary outcome: Feasibility of CalproQuest in daily primary health care practice 
27 GPs completed or partially completed 83 (87.4%) questionnaires consisting of 
seven items. The detailed distribution of answers concerning feasibility of the 
CalproQuest is shown in Figure 2. All items concerning feasibility were assessed 
positive on the four-level even-point Likert scale. Only few GPs stated that they 
prescribe calprotectin tests in patients with ongoing gastrointestinal symptom’s 
regularly and therefore do not need the CalproQuest.  
 
Secondary outcome: Patient-reported acceptance of stool sampling 
82 patients (86.3%) completed or partially completed the patient questionnaire 
consisting of a four-level even-point Likert scale with seven items. All patients 
understood the rationale of feces collection and the patient-reported acceptance of 
stool sampling was high (Figure 3).  
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DISCUSSION 
 
Our study showed that the CalproQuest is a feasible instrument for the assessment of 
IBD in primary care and that the patient reported acceptance of and understanding for 
stool sampling was high. 
 
The rationale for the ALERT trial is the reduction of diagnostic delay in IBD patients. 
Since most patients present to their GP with unspecific abdominal complaints first, 
improving diagnostic procedures for diagnosing IBD patients in primary care is one of 
the most important starting points to reduce diagnostic delay. However, following 
factors render the optimal diagnostic procedure extremely challenging in primary care: 
reasons of encounter for digestive disorders are common (5-7%) 20,21 28,29 but the 
prevalence of IBD extremely low (0.2%) 5, compared to a much higher prevalence of 
functional disorders (10-15%)6. In this low prevalence setting, pretest probability for 
positive diagnostic test results such as the calprotectin are naturally low23. Since not all 
patients with unspecific gastrointestinal complaints can undergo invasive endoscopic 
examination, it is of utmost importance, that other non-invasive diagnostic procedures 
are developed to reduce morbidity and mortality of a diagnostic delay in IBD. To 
increase pretest-probability for a positive calprotectin test and hence to increase its 
utility in the primary care setting, an 8-item-questionnaire (CalproQuest) was tested for 
its feasibility in primary care. 
 
Very few studies currently exist to compare our findings. Danese et al. published a 21 
item questionnaire, which was developed by means of a systematic literature review in 
which CD specialists identified “red flags”, i.e. symptoms or sings suggestive of CD30. 
Healthy as well as known CD patients were subjected to the questionnaire and had to 
recall symptoms. The questionnaire was able to successfully discriminate functional 
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disorders from CD. This questionnaire however was not yet prospectively validated and 
not tested for feasibility, which seems necessary considering large content compared 
to the 7 items of the CalproQuest.  
 
Contradictory to findings from other studies31, our study population showed a high 
acceptance concerning stool sampling, probably due to good communication skills of 
the GPs in ours study population. The diagnostic strategy of combining a questionnaire 
with fecal sampling to measure calprotectin levels therefore seems feasible in the 
Swiss primary care setting.  
 
Strengths and limitations  
In the primary care setting this is one of the few existing studies on the noninvasive 
assessment of IBD, almost none of the former studies are prospective and most 
originate from secondary and tertiary care32. To our knowledge, the ALERT trial is the 
first attempt of prospectively developing a questionnaire for the assessment of IBD in 
primary care.  
The according to the sample size calculation targeted number of 80 patients assumed 
necessary for the feasibility testing in our study was more than achieved (n=95). We 
abstained from restrictive inclusion criteria for the participation in the study. Therefore, 
patients represent the typical clientele with unspecific gastrointestinal complaints, 
which the GP is confronted with in daily practice. We therefore consider the study 
population to be representative. The distribution of participating GPs concerning age 
and gender was similar to the statistics of the Swiss Medical Association 33, therefore 
generalizability can be assumed. Nevertheless, a selection bias of motivated GPs as 
well as patients cannot be neglected.  
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Conclusion  
The CalproQuest is a feasible instrument for the assessment of IBD in primary care. 
Further prospective studies concerning the validity and cost-effectiveness of a 
combined use with the calprotectin test in this setting are necessary.  
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FIGURE LEGENDS 
 
Figure 1 Study flow Feasibility of CalproQuest.  
Legend: Neg=negative; Pos=positive. GP: General Practitioner.  
 
Figure 2 Feasibility of CalproQuest in daily primary care practice.  
Legend: Four-level Likert scale: 1 (Strongly disagree) to 4 (Strongly agree).  
 
Figure 3 Patient-reported acceptance of stool sampling.  
Legend: Four-level Likert scale: 1 (Strongly disagree) to 4 (Strongly agree). 
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TABLES 
 
Table 1: CalproQuest (8-item IBD questionnaire) 
 
Type Criteria Yes  
(1) 
No 
(0) 
Comment 
Major 
Does the patient suffer from abdominal pain 
at least 3 times a week for at least 4 weeks?   
   
Does the patient suffer from diarrhea (more 
than 3 bowel movements daily) for 7 
consecutive days? 
   
Does the patient have diarrhea at night-
time/Does the patient awake from sleep 
because of abdominal pain or diarrhea? 
   
Does the patient report bloody stool?    
 
Minor 
 
Does the patient report mucus in stool for 
more than 4 weeks? 
   
Does the patient report unwanted weight 
loss (5% of normal body weight over 6 
months)? 
   
Does the patient present with fever or report 
fever over the last 4 weeks (Temperature > 
38°C)? 
   
Does the patient report fatigue over the last 
4 weeks? 
   
 
